- Poster presentation
- Open Access
Quetiapine in prolonged ICU delirium
© BioMed Central Ltd. 2010
- Published: 1 March 2010
- Drug Therapy
- Emergency Medicine
- Patient Demographic
Delirium affects up to 33% of acutely hospitalized patients. In ICU patients it can prolong the length of stay and increase mortality . The optimal management of delirium requires a calm environment, sleep hygiene and correction of underlying factors (for example, infection). This can be a challenge in the ICU, and drug therapy, commonly haloperidol, clonidine, benzodiazepines or propofol, is often used . Quetiapine, an atypical antipsychotic, has been used in acute delirium outside the ICU . It has few extrapyramidal side effects, a short half-life and is mildly sedating. Our impression was that it had potential in the treatment of delirium.
In a 30-bed tertiary ICU with more than 1,200 admissions annually we reviewed the notes of patients admitted from February 2008 to November 2009 who had a delirium treated with quetiapine. Patients were excluded if they were taking quetiapine prior to admission. The following data were recorded: Richmond Agitation and Sedation Score (RASS), duration of delirium, agents used, patient demographics and adverse events.
Q dose (mg)
Quetiapine was successful in controlling prolonged ICU delirium and allowed weaning of other medications in these patients. It may be a useful delirium therapy. Further studies are required to demonstrate efficacy and safety.